PetMeds Announces Holiday Collection: Wellness-Focused Gifts for Pets and the People Who Love Them
DELRAY BEACH, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc., d/b/a PetMeds and parent company of PetCareRx, (Nasdaq:...
Cancer
PetMeds Announces Holiday Collection: Wellness-Focused Gifts for Pets and the People Who Love Them
DELRAY BEACH, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc., d/b/a PetMeds and parent company of PetCareRx, (Nasdaq:...
BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025
BriaCell presents positive clinical data in three posters at the San Antonio Breast Cancer Symposium (SABCS®) Phase 3 study of...
BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025
BriaCell presents positive clinical data in three posters at the San Antonio Breast Cancer Symposium (SABCS®) Phase 3 study of...
Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors
MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS endometrial cancer, MSI-H...
Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors
MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS endometrial cancer, MSI-H...
Telix and Varian Announce Strategic Theranostics-EBRT Clinical Collaboration
MELBOURNE, Australia and PALO ALTO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”)...
Telix and Varian Announce Strategic Theranostics-EBRT Clinical Collaboration
MELBOURNE, Australia and PALO ALTO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”)...
BlossomHill Therapeutics Announces $84 Million Financing to Accelerate Clinical-Stage Pipeline of Intelligently Designed Cancer Medicines Including First-in-class Macrocyclic OMNI-EGFR™ Inhibitor for NSCLC
Proceeds to further advance clinical development of BH-30643, a first-in-class, macrocyclic, CNS-active, mutant-selective OMNI-EGFRTM inhibitor for EGFR-mutant NSCLC, and BH-30236,...
BlossomHill Therapeutics Announces $84 Million Financing to Accelerate Clinical-Stage Pipeline of Intelligently Designed Cancer Medicines Including First-in-class Macrocyclic OMNI-EGFR™ Inhibitor for NSCLC
Proceeds to further advance clinical development of BH-30643, a first-in-class, macrocyclic, CNS-active, mutant-selective OMNI-EGFRTM inhibitor for EGFR-mutant NSCLC, and BH-30236,...
JASCAYD® (nerandomilast) receives first regulatory approval for progressive pulmonary fibrosis in China
The approval marks the first new treatment option for people living with progressive pulmonary fibrosis (PPF) in more than five...
JASCAYD® (nerandomilast) receives first regulatory approval for progressive pulmonary fibrosis in China
The approval marks the first new treatment option for people living with progressive pulmonary fibrosis (PPF) in more than five...
Rakovina Therapeutics Announces Upcoming Webinar with Variational AI
From Handshake to Breakthrough: How Rakovina & Variational AI Are Cracking the Code on CNS-Penetrant Cancer TherapiesVANCOUVER, British Columbia, Dec....
Rakovina Therapeutics Announces Upcoming Webinar with Variational AI
From Handshake to Breakthrough: How Rakovina & Variational AI Are Cracking the Code on CNS-Penetrant Cancer TherapiesVANCOUVER, British Columbia, Dec....
Oxford BioTherapeutics Enters into a Strategic Collaboration with GSK to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer
Collaboration leverages OBT's proprietary OGAP®-Verify platform and GSK's drug development expertise to advance multiple selected novel oncology targetsThe agreement -...
Oxford BioTherapeutics Enters into a Strategic Collaboration with GSK to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer
Collaboration leverages OBT's proprietary OGAP®-Verify platform and GSK's drug development expertise to advance multiple selected novel oncology targetsThe agreement -...
Over 20 Studies of InnoCare’s Orelabrutinib Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)
BEIJING, Dec. 09, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the...
Over 20 Studies of InnoCare’s Orelabrutinib Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)
BEIJING, Dec. 09, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the...
Onco-Innovations Chairs Colorectal Cancer Canada Precision Oncology Forum Generating Roadmaps for the Next Era of Cancer Care
VANCOUVER, BC / ACCESS Newswire / December 9, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H, WKN: A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company")...
Westchester Medical Center and Good Samaritan Hospital Recognized as Top Maternity Hospitals by U.S. News & World Report
VALHALLA, N.Y., Dec. 9, 2025 /PRNewswire/ -- U.S. News & World Report (U.S. News) has named Westchester Medical Center and Good Samaritan...